ArticleMaterials today. Bio2025
Glycyrrhizic acid-based nanotheranostic system to enhance photothermal immunotherapy by suppressing HSP90 and remodeling tumor microenvironment.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- T-cell activity feedback-guided photothermal immunotherapy enabled by immune-responsive redox nanodots.Materials today. Bio · 2026Article
- A bibliometric analysis of research trends and emerging frontiers in heat shock proteins and hepatocellular carcinoma from 2015 to 2025.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anticancer photothermal therapy efficacy is currently restricted by heat shock protein (HSP90)-mediated thermoresistance, immunosuppressive microenvironment, and poor delivery efficiency of photosensitizers. At present, the "all-in-one" therapeutic system that can simultaneously achieve tumor-targeted delivery, efficient photothermal therapy, and tumor immune enhancement effects is desperately needed. We previously fabricated Glycyrrhizic acid (GL)-based lipid nanoparticles (GLPs) that possess hepatocellular carcinoma (HCC) targeting and improved membrane stability. Interestingly, GL exhibits the potential to inhibit the up-regulated HSP90 and regulate the immunosuppressive tumor microenvironment. Herein, the near-infrared photosensitizer IR780 was efficiently encapsulated into GLPs to promote photothermal enhancement and synergistic immunosuppressive anti-tumor effects. Under the irradiation of NIR light, the IR780 GLPs effectively enhance the PTT efficacy on the HCC-bearing mice model via suppressing HSP90 expression with the combination of GL. Furthermore, IR780 GLPs exhibited strong HCC targeting ability, effectively downregulating the expression of immunosuppressive Treg cells, promoting the repolarization of M2 macrophages to M1 macrophages, increasing the infiltration of cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.